Rezok-DSR

OVERDOSAGE: Because strategies for the management of overdose are continually evolving, it is advisable to contact a Poison Control Center to determine the latest recommendations for the management of an overdose of any drug. There has been no experience with large overdoses with rabeprazole. Seven reports of accidental overdosage with rabeprazole have been received. The maximum reported overdose was 80 mg. There were no clinical signs or symptoms associated with any reported overdose. Patients with Zollinger-Ellison syndrome have been treated with up to 120 mg rabeprazole QD. No specific antidote for rabeprazole is known. Rabeprazole is extensively protein bound and is not readily dialyzable. In the event of overdosage, treatment should be symptomatic and supportive. 

UNDESIRABLE EFFECTS: Most Common Effect: Headache was the only side effect that occurred in more than 2 percent of people in clinical trials with rabeprazole. Gastrointestinal Side Effects: Several gastrointestinal side effects are rarely associated with rabeprazole. These include constipation or diarrhea, increased or decreased appetite, stomach pain, upset stomach, nausea and vomiting. Other Side Effects: Other unlikely rabeprazole side effects include dizziness, drowsiness, dry mouth, insomnia , nervousness, water retention, and muscle or bone pain. Long-Term Use: A rare side effect with long-term use of over three years is vitamin B-12 deficiency, with symptoms of weakness, sore tongue, and numbness or tingling in the hands or feet.

UNDESIRABLE EFFECTS: Most Common Effect: Headache was the only side effect that occurred in more than 2 percent of people in clinical trials with rabeprazole. Gastrointestinal Side Effects: Several gastrointestinal side effects are rarely associated with rabeprazole. These include constipation or diarrhea, increased or decreased appetite, stomach pain, upset stomach, nausea and vomiting. Other Side Effects: Other unlikely rabeprazole side effects include dizziness, drowsiness, dry mouth, insomnia , nervousness, water retention, and muscle or bone pain. Long-Term Use: A rare side effect with long-term use of over three years is vitamin B-12 deficiency, with symptoms of weakness, sore tongue, and numbness or tingling in the hands or feet.

CONTRAINDICATIONS: Rabeprazole is contraindicated in patients with known hypersensitivity to rabeprazole, substituted benzimidazoles or to any component of the formulation. Clarithromycin is contraindicated in patients with known hypersensitivity to any macrolide antibiotic. Concomitant administration of clarithromycin with pimozide and cisapride is contraindicated. There have been post-marketing reports of drug interactions when clarithromycin and/ or erythromycin are co-administered with pimozide resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsade de pointes) most likely due to inhibition of hepatic metabolism of pimozide by erythromycin and clarithromycin. Amoxicillin is contraindicated in patients with a known hypersensitivity to any penicillin.

DOSAGE AND ADMINISTRATION: One capsule once daily. Special populations: Geriatric: In 20 healthy elderly subjects administered 20 mg rabeprazole once daily for seven days, AUC values approximately doubled and the Cmax increased by 60% compared to values in a parallel younger control group. There was no evidence of drug accumulation after once daily administration. Pediatric: The pharmacokinetics of rabeprazole was studied in 12 adolescent patients with GERD12 to 16 years of age, in a multicenter study. Patients received rabeprazole 20 mg once daily for five or seven days. An approximate 40% increase in exposure was noted following 5 to 7 days of dosing compared with the exposure after 1 day dosing. Pharmacokinetic parameters in adolescent patients with GERD 12 to 16 years of age were within the range observed in healthy adult volunteers. Gender: In analyses adjusted for body mass and height, rabeprazole pharmacokinetics showed no clinically significant differences b...

INDICATIONS: REZOK-DSR is indicated for the relief of symptoms of: Dyspepsia GERD Nausea associated with acid peptic disorders Post-operative nausea and vomiting Chronic gastritis Reflux esophagitis Diabetic gastropathy Non cardiac heart burn Post prandial fullness Stomach and duodenal ulcers Zollinger Ellison Syndrome (ZES)

REZOK-DSR: Highlights Rabeprazole: It blocks the production of acid by the stomach. Greater efficacy than Esomeprazole. Increases intragastric pH for longer duration. More effective in comparison with omeprazole in: o    Daytime symptomic relief in GERD. o    H.pylori eradication                       ·    Rapid and well tolerable therapy in Zollinger-Ellison syndrome than Omeprazole and Lansoprazole. Food has non effect on its absorption.   Minimal propensity for Drug Interaction. Rapid and Complete heartburn relief. 2-10 times greater Anti-secreatory effect than Omeprazole. The acid suppressive effect of Rabeprazole seen at concentration 10mg is minimum which is least as compared to Omeprazole and Lansoprazole. Fastest relief from heart burn, bloating and belching. It prevents acid reflux. Faster gastric emptying. First standard Pro...

Rezok-DSR capsules contains the combination of Rabeprazole 20mg + Domperidone 30mg in the form of well made granules tightly packed in the hard gel capsules under strict supervision of WHO-cGMP provisions. The quality is best keeping in view all the requirements of the patients to whom the product is being or will be prescribed. The patient should dwell the compete benefit of the drugs used and keeping this in view has the quality of the product been maintained. Batch-wise consistency of the product is also maintained. It is available in alu-alu packing and the current M.R.P. is Rs. 75/- per strip of 10 capsules. Each box contains 10 strips; each having 10 capsules. Product at a glance

Rezok-DSR is composed of two components: Rabeprazole; which is a proton-pump inhibitor in the strength of 20mg along with 30mg of Domperidone; i.e., an anti-emetic. It is a brand of Brenstem Biosciences. Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole protonpump inhibitors) that do not exhibit anticholinergic or histamine H 2 -receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H + /K + ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. Domperidone is a derivative of benzimidazole that possesses both prokinetic and antiemetic properties due to its inhibitory action ...